Nusinersen: First Global Approval

Drugs

Volumn 77, Issue 4, 2017, Pages 473-479

  Hoy, Sheridan M ^a  

^a SPRINGER   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; NUSINERSEN; SURVIVAL MOTOR NEURON PROTEIN; SURVIVAL MOTOR NEURON PROTEIN 2; ANTISENSE OLIGONUCLEOTIDE; OLIGONUCLEOTIDE;

ADVERSE OUTCOME; ARTICLE; ATELECTASIS; BACKACHE; CONSTIPATION; DRUG APPROVAL; DRUG LEGISLATION; EXON; GENE DELETION; GENE MUTATION; GENETIC TRANSCRIPTION; HEADACHE; HUMAN; HYPONATREMIA; INTRON; NEUTROPENIA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PNEUMONIA; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; SIDE EFFECT; SPINAL MUSCULAR ATROPHY; THROMBOCYTE COUNT; UPPER RESPIRATORY TRACT INFECTION; VOMITING; ANIMAL; CHEMISTRY; MUSCULAR ATROPHY, SPINAL; UNITED STATES;

ANIMALS; DRUG APPROVAL; HUMANS; MUSCULAR ATROPHY, SPINAL; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; UNITED STATES;

EID: 85013474211     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.1007/s40265-017-0711-7     Document Type: Article

References (16)

1. Castro D, Iannaccone ST. Spinal muscular atrophy: therapeutic strategies. Curr Treat Options Neurol. 2014;16(11):316.
2. Farrar MA, Park SB, Vucic S, et al. Emerging therapies and challenges in spinal muscular atrophy. Ann Neurol. 2016. doi:10.1002/ana.24864.
3. US National Library of Medicine. Genetics Home Reference: spinal muscular atrophy. 2017. https://ghr.nlm.nih.gov/. Accessed 16 Jan 2017.
4. Lefebvre S, Burglen L, Reboullet S, et al. Identification and characterization of a spinal muscular atrophy-determining gene. Cell. 1995;80(1):155–65.
5. Garber K. Big win possible for Ionis/Biogen antisense drug in muscular atrophy. Nat Biotech. 2016;34(10):1002–3.
6. Biogen Inc. SPINRAZA (nusinersen) injection, for intrathecal use: US prescribing information. 2016. http://www.fda.gov/. Accessed 9 Jan 2017.
7. US Food and Drug Administration. FDA approves first drug for spinal muscular atrophy. 2016. http://www.fda.gov. Accessed 17 Jan 2017.
8. Biogen. US FDA approves Biogen’s SPINRAZA™ (nusinersen), the first treatment for spinal muscular atrophy. 2016. https://www.biogen.com/. Accessed 9 Feb 2017.
9. Biogen. Biogen and Ionis Pharmaceuticals announce SPINRAZA (nusinersen) meets primary endpoint at interim analysis of phase 3 CHERISH study in later-onset spinal muscular atrophy. 2016. http://www.biogen.com/. Accessed 26 Jan 2017.
10. US FDA Center for Drug Evaluation and Research. Medical review(s). 2016. http://www.fda.gov/. Accessed 24 Jan 2017.
11. Finkel RS, Chiriboga CA, Vajsar J, et al. Treatment of infantile-onset spinal muscular atrophy with nusinersen: a phase 2, open-label, dose-escalation study. Lancet. 2017;388(10063):3017–26.
12. US FDA Center for Drug Evaluation and Research. Clinical pharmacology and biopharmaceutics review(s). 2016. http://www.fda.gov/. Accessed 24 Jan 2017.
13. Chiriboga CA, Swoboda KJ, Darras BT, et al. Results from a phase 1 study of nusinersen (ISIS-SMN(Rx)) in children with spinal muscular atrophy. Neurology. 2016;86(10):890–7.
14. Biogen. Biogen and Ionis Pharmaceuticals report nusinersen meets primary endpoint at interim analysis of phase 3 ENDEAR study in infantile-onset spinal muscular atrophy. 2016. http://www.biogen.com/. Accessed 17 Jan 2017.
15. Biogen. New data presented at World Muscle Society Congress support potential benefit of investigational treatment nusinersen in spinal muscular atrophy. 2016. http://www.biogen.com/. Accessed 26 Jan 2017.
16. Darras B, Chiriboga C, Swoboda K, et al. Results of a phase 2 study of ISIS-SMNRx in children with spinal muscular atrophy [abstract no. G.O.18]. Neuromuscul Disord. 2014;24(9–10):920.